For many first-time claimants, Advance Assurance can be useful, but only in a narrow set of cases. It helps eligible small companies reduce uncertainty before a first claim, but it does not replace claim notification, the Additional Information Form, or the need for a robust technical and financial filing.
If you are a cautious CFO, Finance Director, or founder preparing a first R&D tax relief claim, the real question is not simply whether Advance Assurance exists. The real question is whether it is the right certainty tool for your company, your timeline, and your claim risk.
This matters more now because HMRC’s compliance environment has changed. First claims are under greater scrutiny, structured reporting now sits earlier in the process, and HMRC is actively exploring broader assurance and pre-clearance routes. That makes Advance Assurance relevant again, but not always decisive.
Advance Assurance is a voluntary HMRC process that can give certain first-time SME claimants confidence that their first claims will be accepted if they match what HMRC reviewed. It is designed to reduce uncertainty before the claim is filed.
In practical terms, Advance Assurance lets an eligible company share details of its R&D work with HMRC before claiming relief through its CT600. If HMRC agrees that the relief applies, the company receives an agreement that covers its first three accounting periods, provided the claims stay in line with what was discussed and agreed.
That sounds attractive, especially to boards that want certainty before investing internal time in a new claim process. But it is important to understand what Advance Assurance is not:
Yes, if you are eligible and uncertainty is the main reason you are hesitating. No, if you are using it as a substitute for a well-prepared first claim.
The right answer depends on your situation. For some businesses, Advance Assurance is a sensible first step because it gives management comfort and helps unlock a claim that would otherwise be delayed. For others, it creates extra process without solving the real issue, which is usually weak technical framing, unclear cost treatment, or a lack of claim-readiness.
A simple decision rule is this:
Situation |
Advance Assurance likely to help? |
Why |
| Small first-time claimant, eligible, management wants early certainty | Yes | It can reduce hesitation and create confidence before filing |
| First-time claimant, but not eligible due to size or group history | No | You cannot use the scheme |
| Company already ready to file with strong evidence and clear methodology | Maybe not | The extra step may add friction rather than value |
| Business wants certainty on a complex issue outside the current narrow route | Not usually | The current route is limited and not a bespoke pre-clearance service |
| Board is worried about enquiry risk but the claim process is weak | No, not on its own | The bigger issue is evidence, governance, and technical quality |
Advance Assurance is aimed at first-time SME claimants with turnover below £2 million and fewer than 50 employees. If you fall outside those criteria, it is generally not the right route.
At the time of writing, HMRC’s current guidance is focused on smaller first-time claimants. That means you are broadly looking at a company that:
This matters because many businesses searching for “R&D pre-clearance” assume the option is open to all claimants. It is not. For many scaling businesses, software companies, PE-backed groups, and more mature claimants, the issue is not whether Advance Assurance is desirable. It is that the current route may not be available.
Advance Assurance sits alongside the first-claim process. It does not replace the mandatory steps that HMRC now expects before a valid claim is submitted.
This is where many first-time claimants get confused. The process now has more moving parts than it did a few years ago, and boards often treat them as interchangeable. They are not.
Step |
What it does |
Is it still needed if you use Advance Assurance? |
| Claim Notification Form | Tells HMRC you intend to claim, if required | Yes |
| Advance Assurance | Gives eligible first-time SMEs early confidence | Optional |
| Additional Information Form | Provides project and cost detail before filing | Yes |
| CT600 claim | Formally submits the relief claim | Yes |
This is why a purely “do we qualify?” article is no longer enough. The CFO audience needs to understand workflow risk. A company can be technically eligible for relief and still fail the process if it misses claim notification deadlines, submits the AIF late, or files the CT600 before the AIF.
Advance Assurance helps most when confidence, not capability, is the barrier.
There are several circumstances where it can be commercially sensible:
If the finance team or leadership group is worried that a first claim could trigger avoidable compliance issues, Advance Assurance can reduce psychological resistance and move the project forward.
For early-stage and smaller SMEs, especially those without an internal tax function, the scheme can be a useful bridge between “we think we qualify” and “we are comfortable filing”.
For cash-sensitive businesses, a first claim is often about more than tax. It can support runway, hiring, or investor messaging. In that context, additional certainty can be valuable if it prevents internal delays.
Some companies use the process to force early discipline around project selection, technical explanation, and cost mapping. Done properly, that can strengthen all three of the first covered periods.
Advance Assurance does not help when the real issue is claim quality, not claim confidence.
That distinction is critical.
If your baseline, technological uncertainty, or advance is poorly framed, the problem is not the lack of assurance. The problem is the claim itself.
You still need to get the timing, forms, and scheme treatment right. A company can receive assurance and still create downstream issues if it mishandles claim notification, AIF sequencing, subsidy treatment, or qualifying expenditure.
Many CFOs imagine a process where HMRC clears the whole claim strategy in advance. That is not how the current route works. It is narrower, more specific, and more restricted in who can use it.
If you have good evidence, strong project narratives, correct scheme treatment, and a disciplined filing process, the additional step may add delay without adding much practical value.
It can reduce risk for eligible companies if the final claim stays aligned to what HMRC agreed, but it is not a blanket shield against weak filing practice.
This is where nuanced positioning matters.
Advance Assurance can give a legitimate first-time claimant useful comfort. But enquiry risk is not created by one factor alone. Risk is shaped by the quality of your technical explanation, the traceability of your costs, the consistency of your story across forms, and the evidence behind the numbers.
The safest first claim is built on evidence, governance, and period-correct filing, whether or not Advance Assurance is used.
For most first-time claimants, that means building a simple but robust claim-readiness pack before submission:
This is also the right place to challenge a common mistake in the market. Many businesses treat first claims as exploratory and low-stakes. In reality, first claims often set the tone for future claims, future evidence expectations, and future interactions with HMRC.
HMRC is actively exploring wider assurance and advance clearance routes, so the topic is becoming more important, not less.
The policy direction matters here. HMRC consulted on broader R&D tax relief advance clearances in 2025, looking at how a more developed assurance model could reduce error, improve customer experience, and give businesses more certainty earlier in the process. The consultation has now concluded, and a targeted pilot is due to launch in Spring 2026.
That does not mean the answer for every business is to wait for a new service. It means finance leaders should recognise that pre-assessment is becoming part of the strategic conversation. Companies that build stronger evidence and governance now will be better placed whatever assurance routes expand next.
The UK is not alone in moving towards earlier scrutiny and pre-approval logic. Many jurisdictions already use pre-approval, registration, or advance-finding style processes for innovation incentives.
For multinational groups, this matters because tax certainty is becoming more front-loaded. The UK consultation itself pointed to a wide range of international models where companies must register, seek pre-approval, or obtain a technical finding before or alongside claiming relief.
This is where FI Group by EPSA brings a stronger value proposition than a single-jurisdiction filing provider. We help finance leaders connect Global Reach. Local Expertise. across jurisdictions, aligning local claim mechanics with central governance, documentation discipline, and cross-border risk management.
If your UK entity is making a first claim today, that may seem like a local issue. In practice, it often becomes the template for how the wider group thinks about innovation incentives, evidence, and advisory quality.
FI Group by EPSA is not a commoditised filing service. We support CFOs, founders, and technical teams with evidence-led claim strategy, clear process design, and advisory depth that holds up under a tougher compliance environment.
We help businesses:
For first-time claimants, the value is not just in filing a claim. It is in filing a claim that is worth repeating.
If you are preparing a first R&D tax relief claim and want to know whether Advance Assurance is worth pursuing, FI Group by EPSA can help you make the decision clearly.
We can assess your eligibility, review how Advance Assurance fits your timeline, and strengthen the wider claim process around claim notification, AIF preparation, technical narratives, and cost support.
Talk to FI Group by EPSA about building a first claim that is accurate, defensible, and board-ready.
First-time claimants often have the same concern: they want certainty, but they do not want to create extra process that slows the claim down. The FAQs below answer the most common questions CFOs, founders, and finance teams ask when deciding whether Advance Assurance is worth using.
No. Advance Assurance is voluntary. Eligible companies can choose to apply, but they can still make an R&D tax relief claim through the normal process if they do not use it.
No. If claim notification applies to your accounting period, you still need to complete that step even if you apply for Advance Assurance.
No. You still need to submit the Additional Information Form before, or on the same day as, your CT600 claim.
If successful, the agreement can cover your first three accounting periods, provided the claims remain consistent with what HMRC agreed.
Not under the current narrow route. It is aimed at certain smaller first-time SME claimants.
Miss the Claim Notification Form deadline and the technical quality of your R&D claim may stop mattering. For first-time and lapsed claimants, the filing position can be simple: notify HMRC in time, or lose the claim for that period. The form is separate from the Additional Information Form and the CT600.
Finance teams also need to look at the timing risk in context. HMRC says it checked 17% of claims in 2023 to 2024, the average compliance check took 246 days, and 77% of settled checks required an adjustment. That is a cash flow issue, a governance issue, and a workload issue.
The Claim Notification Form is HMRC’s advance notice requirement for certain companies intending to claim R&D tax relief. It is not the claim itself, and it does not replace the Additional Information Form or the Company Tax Return.
The rule sits inside the reformed R&D claims process introduced after the Finance (No. 2) Act 2023. HMRC’s internal manual ties the claims process to the Corporation Tax Act 2009, and the 2023 Regulations set out the information that must be included in a claim notification.
You usually need to submit a Claim Notification Form if you are claiming R&D tax relief for the first time, or if your last claim was made more than three years before the last day of the claim notification period.
In practice, that usually catches:
HMRC also lists two published exceptions where a previous claim does not remove the need to notify:
There is one further point that matters. If the actual R&D claim reaches HMRC by the last day of the claim notification period, that can remove the need for a separate form. Many companies miss that detail, then leave the work too late for it to help them.
Scenario |
Claim Notification Form needed? |
| First-ever R&D claim | Yes |
| Recent valid claim inside the three-year lookback, with no exceptions | Usually no |
| Previous R&D claim removed by HMRC from the return | Yes |
| Previous claim for a pre-1 April 2023 period made by amendment received on or after 1 April 2023 | Often yes |
| Long period of account covering more than one accounting period | One notification can cover the period of account, if notification is needed |
The detail still needs to be checked against the company’s own dates and filing history.
The deadline is the end of the “claim notification period”, which runs from the first day of the period of account to six months after the end of that period of account. Miss that deadline and the R&D claim can be invalid.
This is where many finance teams trip up. HMRC does not ask you to look only at the accounting period on the CT600. You also need to understand the period of account used in the financial statements.
For many businesses with a normal 12-month year end, the timing is straightforward. If your period of account ends on 31 March 2025, the last date to notify is 30 September 2025.
For long periods of account exceeding 12 months, the position is more technical. A single period of account can contain two accounting periods for Corporation Tax, but HMRC applies the same claim notification period across those accounting periods. That means one timely notification can cover the accounting periods falling within that same period of account.
| Scenario | Does the company need to notify? | Practical deadline |
| First-ever R&D claim, year end 31 March 2025 | Yes | 30 September 2025 |
| Claimed recently within the relevant three-year window | Usually no | No separate notification needed |
| Last valid claim was too old to fall within the lookback | Yes, unless the actual claim is filed by the last date of the claim notification period | Six months after period of account end |
| 18-month period of account with two CT accounting periods | Often yes for first-time or lapsed claimants, but one notification can cover both periods in that same period of account | Six months after the end of the full period of account |
These examples apply HMRC’s current timing rules and are useful for internal planning, but finance teams should still map the exact dates against the company’s own year-end structure.
A company does not usually need to submit the form if it has made an R&D claim within the three years ending with the last day of the claim notification period, unless one of HMRC’s stated exceptions applies.
There is another important nuance. If a company needs to notify, it can still avoid a separate notification form if the actual R&D claim itself is received by HMRC on or before the last date of the claim notification period. In other words, the claim can sometimes satisfy the timing requirement if it is filed early enough.
That point is valuable for CFOs because it turns the issue into a timetable question, not just a tax technicality. If your finance team will not have the technical narrative, cost schedules, and governance approvals ready early, you should not assume the claim can simply be accelerated to solve the problem.
HMRC’s internal manual, updated in March 2026, records an administrative easement for certain companies affected by incorrect HMRC guidance published between September and October 2024. The easement is narrow and fact-specific, so it should not be treated as a general safety net.
The Claim Notification Form, if required, comes first. The Additional Information Form must then be filed before, or on the same day as, the CT600 claim. Missing either step can invalidate the R&D claim.
For most claimants, the filing sequence should look like this:
This is why finance leaders should treat claim notification as part of claim governance, not as a minor admin step. The technical narrative might be excellent, but the claim can still fail on process.
The biggest mistakes are timing errors, filing sequence errors, and overconfidence in old processes. In the current compliance environment, those mistakes can create cash flow delays, management distraction, and a harder path for future claims.
The most common issues are:
This is the classic deadline error. Teams look at the CT600 period but forget the statutory deadline is tied to the period of account.
The exemption is not a vague “we claimed once before”. It is a specific three-year lookback test, with published exceptions.
HMRC’s guidance is explicit. If the AIF is filed after the return, the R&D claim can be rejected.
The form is only an early notice. The real evidential burden still sits in the AIF, the CT600, and the supporting technical and financial records.
For CFOs, this is where process risk becomes business risk. HMRC’s own 2023 to 2024 figures show both higher compliance coverage and long resolution times, which means poor filing discipline can turn into a serious cash flow issue.
A good process starts early, has named internal ownership, and leaves enough time between each filing step. It does not rely on year-end guesswork.
A practical checklist for finance teams:
The Claim Notification Form is not just a tax form. It is an early control point in the wider governance of your R&D claim. If you miss it, the problem is binary. If you get it right, you still need the AIF, CT600 accuracy, and evidence stack behind the claim.
For finance leaders, the real issue is predictability:
That is why this topic should be owned as part of the annual compliance calendar, not parked until the tax return is nearly ready.
The UK still relies mainly on notification plus post-claim checking, but the policy direction is moving towards more targeted pre-claim assurance. HMRC concluded its consultation on R&D tax relief advance clearances and says it will launch a limited pilot of a new targeted advance assurance service in Spring 2026, while the existing advance assurance offer continues.
That matters for multinational and internationally ambitious groups. HMRC’s consultation notes that many countries already use some form of pre-approval or advance assurance, while the UK is exploring a more targeted model. HMRC also notes that its current advance assurance process has had very low uptake.
For UK groups with overseas operations, the wider lesson is clear: R&D incentives are becoming more process-driven, more evidence-led, and more front-loaded. FI Group by EPSA’s value in that environment is the ability to align HQ strategy with local filing rules, so your UK claim notification, AIF, and wider international governance all work together.
FI Group by EPSA helps CFOs and finance teams turn R&D tax relief from a reactive filing exercise into a controlled process.
We support clients by:
That is where Global Reach. Local Expertise. becomes practical, not just promotional. One group standard, applied properly to the UK rules.
This section answers the questions finance teams most often ask when planning an R&D claim.
Yes. “Advanced Notification Form” or ANF is common market shorthand, but HMRC’s current guidance uses Claim Notification Form.
No. You usually only need it if you are a first-time claimant or your last qualifying claim falls outside the relevant three-year lookback, subject to HMRC’s exceptions.
Yes. HMRC says the form can be submitted by a company representative or an authorised agent.
Not always. HMRC says the actual R&D claim can satisfy the timing requirement if it is received by the last date of the claim notification period.
Yes, where those accounting periods fall within the same period of account, the claim notification period is the same.
No. The Claim Notification Form is an advance notice requirement for certain claimants. The AIF is the detailed information HMRC requires before or alongside the claim itself.
HMRC’s guidance says the R&D claim can be rejected if the AIF is filed after the return.
No. Advance assurance is a separate voluntary HMRC process. The current public guidance says it is aimed at first-time SME claimants below certain size thresholds, and HMRC is also developing a more targeted pilot.
Yes. HMRC’s manuals were updated in March 2026, and HMRC has also confirmed a targeted advance assurance pilot is due to launch in Spring 2026.
Build the claim timetable backwards from the period of account end date, check notification status early, prepare the AIF before the CT600, and do not rely on prior filing habits.
In an R&D claim, the competent professional is the person whose technical judgement helps establish whether the work sought a genuine advance in science or technology, whether scientific or technological uncertainty existed, and where the qualifying R&D began and ended. If that judgement is weak, the whole claim becomes harder to defend.
For many businesses, this is where the claim either becomes clear and credible or vague and exposed. The role is not administrative. It goes to the centre of how qualifying R&D is assessed.
A competent professional is someone with the right qualifications or practical experience in the relevant field to judge whether a project sought an advance in science or technology and whether the answer was not readily deducible at the outset.
This is not just a question of seniority. A founder, CTO, technical director or lead engineer may be the right person, but title alone does not decide it. The real test is whether that person can explain:
That matters because HMRC does not assess a project against what was new to your business. It looks at what was known, or could readily be worked out, by a competent professional working in the field.
The competent professional matters because the core R&D test depends on expert technical judgement.
A claim needs someone who can explain why the project involved more than routine development, routine engineering, or ordinary problem-solving. That person should be able to show why the uncertainty was genuine, why the solution was not obvious at the outset, and why the work represented an advance in the field rather than only an internal improvement for the company.
This is also why weak claims often struggle. They may describe a complex commercial project, but they do not explain the underlying scientific or technological uncertainty clearly enough. Without a credible technical voice behind the narrative, the claim can drift into general business description rather than a defensible R&D position.
The competent professional can be internal or external, provided they have the right technical depth in the field that matters for the project.
In practice, that may be:
What matters is fit. If the project concerns embedded systems, complex software architecture, novel materials, process engineering, data infrastructure or medtech development, the competent professional should have genuine expertise in that area.
The wrong choice is often obvious in hindsight. A commercially senior person may know the business extremely well, but still be the wrong person to judge the underlying scientific or technological question.
The competent professional should help define four things clearly:
Question |
What the claim should show |
| What was the baseline? | What was already known or readily deducible in the field |
| What was the advance? | The improvement in science or technology being sought |
| What was the uncertainty? | Why the answer was not readily available at the start |
| Where did the R&D begin and end? | Which activities directly contributed to resolving that uncertainty |
This point is important because not every activity in a wider commercial project qualifies. A project may include concept design, trials, testing, scale-up, implementation, quality assurance, commercial deployment and customer support. Only some of those stages may involve qualifying R&D.
The competent professional helps identify the boundary properly. That creates a stronger technical narrative and usually supports better cost discipline too.
This is one of the most important distinctions in an R&D claim.
A technical challenge may be difficult, expensive, time-sensitive or commercially important. That does not automatically make it qualifying R&D.
A technological uncertainty exists where it is not readily deducible by a competent professional whether something is scientifically or technologically possible, or how it can be achieved in practice.
That is why businesses sometimes overstate qualifying activity. A project can involve real pressure, ambitious targets and demanding delivery work without meeting the R&D test. The issue is not how hard the work felt internally. The issue is whether the scientific or technological answer was genuinely uncertain at the outset.
No, but they should shape the technical case early and review it properly before submission.
Finance teams and advisers can structure the claim, prepare the cost analysis and assemble the filing. But the technical core should come from the person best placed to judge the advance and the uncertainty.
Where businesses often go wrong is timing. They draft a broad narrative first, then ask the technical lead to approve it at the end. That usually produces weak language, blurred boundaries and generic explanations.
A stronger process starts with the technical conversation. The competent professional should help define:
A name on a form is not enough. The claim should make clear why that person was the right person to judge the project.
Useful evidence may include:
That evidence does not need to dominate the page, but it should support the credibility of the technical narrative. A strong claim shows both the substance of the uncertainty and the credibility of the person explaining it.
Yes, but that does not remove the need for internal accountability. HMRC says the competent professional may be external. In some cases that is the best option, especially where the company lacks depth in-house.
At the same time, HMRC’s claims process still places responsibility on the claimant company. Where a claim notification is required, HMRC asks for the main senior internal R&D contact responsible for the claim. For the Additional Information Form, HMRC also expects project descriptions that explain the uncertainties and the activities used to resolve them, and it allows a separate report with more detail on methodology and competent professionals.
The practical answer is usually a blend. Internal technical owners provide project reality. Specialist advisers help turn that into a cleaner, more defensible claim.
The most common errors are usually straightforward.
Some companies default to the most senior person in the business. Others default to whoever signs off the claim. Neither approach is reliable. The competent professional should be chosen because of field-specific technical depth.
A weak claim often compares the project against what the company knew internally, rather than what was already known in the field. That makes ordinary development work sound more novel than it really was.
A project may be complex, expensive or commercially risky without involving qualifying R&D. The claim needs to show genuine scientific or technological uncertainty, not just a demanding delivery environment.
If the technical lead only sees the draft at the end, important detail is often missed. Baseline, uncertainty and project boundaries should be set early.
Phrases such as “complex project”, “significant challenge” or “innovative solution” do not carry enough weight on their own. The claim should say what was uncertain, why it was uncertain, and what work addressed it.
In software claims, the competent professional is often a senior architect, engineering lead or principal developer. The claim should explain why the uncertainty related to architecture, integration, performance, scalability, security or system behaviour, rather than standard development work.
In engineering claims, the competent professional may be a lead design engineer, process engineer or technical director. The narrative should show what was already known in the field, what constraints applied, and why the answer could not readily be worked out at the start.
In life sciences, the competent professional is often a senior scientist, formulation lead, technical director or specialist consultant. The claim needs to distinguish genuine scientific or technological uncertainty from regulatory, commercial or operational hurdles.
For leadership teams, the competent professional question is really about claim quality, governance and resilience.
If the technical ownership is weak, three problems usually follow:
That is why this issue matters beyond tax compliance. It affects cash flow, internal effort and confidence in the wider R&D claim process.
While the phrase competent professional is specific to UK R&D tax language, the underlying issue is broader. International groups still need the right technical decision-makers, consistent evidence standards and a clear link between technical work and claim preparation.
For businesses operating across multiple jurisdictions, that means balancing local technical depth with wider group-level governance. FI Group by EPSA supports clients through a model that combines global reach with local expertise, helping businesses align technical evidence with country-specific requirements while maintaining a clearer overall funding and innovation strategy.
FI Group by EPSA helps businesses identify the right competent professional, frame the baseline correctly, and build stronger technical narratives around qualifying R&D.
That can include:
If your business is carrying out genuine R&D but your claim still relies on broad project summaries, FI Group by EPSA can help turn technical complexity into a clearer, more defensible filing.
No. The role depends on technical competence in the relevant field, not board status.
Yes, if the CTO has the right technical depth in the field and can judge the baseline, the advance and the scientific or technological uncertainty.
Yes. An external expert may be appropriate where the company does not have enough in-house technical depth.
No. Different projects may require different specialists depending on the field and the uncertainty involved.
Not necessarily, but their judgement should shape the technical case and the way qualifying projects are described.
Useful records may include design notes, test results, technical meeting notes, failed attempts, prototype evidence and documents showing how the uncertainty was addressed.
Yes. Software projects still need someone qualified to judge whether scientific or technological uncertainty existed.
That may still be a genuine technical challenge for the business, but it is less likely to meet the R&D tax definition.
Ideally at the start of claim preparation, while project scoping and technical interviews are still underway.
Quantum funding in 2026 is no longer a single story. The UK’s ten-year £2.5 billion quantum strategy still sets the long-term direction, but the near-term picture is now much clearer: more emphasis on mission-led adoption, commercialisation infrastructure, and real-world deployment. That direction was reinforced again on 17 March 2026, when the government announced a fresh quantum package worth up to £2 billion focused on scaling capability and deployment.
Key points at a glance
The UK’s five quantum missions make the policy direction easier to read than it was a year ago. Two of those missions are long-range, with 2035 goals around computing and networking. Three are closer-term, with 2030 goals tied to healthcare sensing, resilient navigation and mobile sensing for critical infrastructure. That matters because it shows where government wants adoption to happen first.
The funding pattern now broadly matches those missions. Innovate UK’s November 2025 quantum awards put more than £14 million into 14 projects, with a clear emphasis on sensing and quantum-enabled position, navigation and timing rather than a narrow computing-only story.
No. Quantum computing remains a core national priority, but the funding architecture is broader than that.
Mission 1 still targets accessible UK-based quantum computers capable of running 1 trillion operations by 2035, while Mission 2 targets a quantum network at scale by the same date. But Missions 3, 4 and 5 show equal policy intent around adoption in healthcare, aircraft navigation and critical infrastructure. In other words, quantum funding in 2026 is increasingly split between long-horizon computing capability and nearer-term deployment use cases.
That broader approach is also visible in government announcements. The April 2025 £121 million quantum package focused on applications including fraud prevention, healthcare and energy efficiency, while the March 2026 package moved further towards rollout at scale.
Quantum sensing is one of the strongest short-term funding themes. Mission 3 aims for every NHS Trust to benefit from quantum sensing-enabled solutions by 2030, while Mission 5 targets mobile, networked quantum sensors across transport, telecoms, energy and defence. That makes sensing one of the clearest lanes for businesses with application-led propositions.
PNT is another strong lane. Mission 4 is explicit that by 2030 quantum navigation systems, including clocks, should be deployed on aircraft. In practice, that frames PNT as an infrastructure resilience issue, not just a laboratory advance. Businesses working on GNSS resilience, precision timing and navigation applications are now much easier to map against a visible public priority.
Quantum networking is still strategically important, but it reads more as a scale-building and infrastructure play than an immediate mass-adoption market. Mission 2 is about nationwide connectivity, early commercialisation, standards leadership and international collaboration, which points to a slower but still very important funding lane.
A major shift in the funding landscape is that support is no longer just about single project awards. It is increasingly about translation environments.
In February 2024, UKRI and the National Quantum Computing Centre invested £30 million in quantum computing testbeds. In November 2025, the Harwell Quantum Cluster launched with the aim of creating more than 1,000 high-value jobs and bringing £1 billion of investment into the UK over the next decade. Alongside that, the Commercialising Quantum Technologies Challenge invested more than £174 million, backed by more than £390 million from industry, between 2018 and 2025. Together, those signals point to a more mature commercialisation model: not just grants for invention, but infrastructure for scaling, testing and attracting private capital.
As of 27 March 2026, these are some of the most relevant routes for quantum businesses:
For quantum businesses trying to turn technical progress into a workable funding strategy, FI Group by EPSA can help align grant opportunities, collaborative programmes and wider non-dilutive incentives with commercial milestones, evidence requirements and application timing.
The clearest near-term signals point to quantum sensing, quantum-enabled PNT and infrastructure-led applications, based on the UK missions and recent Innovate UK awards.
Yes. Quantum computing remains central to UK strategy, with Mission 1 targeting UK-based quantum computers capable of 1 trillion operations by 2035, supported by testbeds, NQCC activity and more recent government backing for rollout at scale.
Yes. One of the most visible current routes is the UK-Germany Collaborative Innovation for Quantum Technologies 2026 competition, which offers up to £3 million and closes on 15 April 2026.
Yes. UK researchers and businesses have wider access to Horizon Europe quantum calls, and the 2026 digital work programme includes several quantum-relevant topics.
Because they bridge the gap between research capability and commercial readiness. In practice, they help businesses compare approaches, refine applications and move closer to market adoption.
UKRI’s funding reforms are being presented as a move towards clearer priorities, stronger accountability and a more visible economic return from public research investment. UK Research and Innovation has set out how it will deploy its four-year £38.6 billion allocation, including £8 billion for targeted R&D linked to national and societal priorities, £7 billion for innovative company growth, £14 billion for curiosity-driven research, and further investment in skills and infrastructure. [1]
For the UK’s broader innovation economy, that matters well beyond the university sector. The way this funding is structured will shape what kinds of projects move forward, how research is translated into commercial value, and how resilient the UK’s research base remains across sectors such as life sciences, biotech, drug manufacturing, advanced manufacturing and advanced engineering.
The stated logic behind the reforms is straightforward. In evidence to MPs, UKRI chief executive Sir Ian Chapman argued that the new bucket model should create a clearer line from mission to spend, reduce duplication across councils and make accountability more visible. He also said the previous model, which was organised more by discipline than output, made it difficult to see a coherent programme in areas such as life sciences or other strategically important sectors. [5]
That ambition is understandable. Public funders are under pressure to show how research spending supports growth, industrial strategy and real-world outcomes. But the central issue is not whether priorities should be clearer. It is whether the transition is being handled in a way that protects the university base on which much of that future value depends.
The strongest public criticism so far has come from the BMJ, which argues that UKRI has not been fully transparent about how the projected allocations across the three buckets were calculated and that the detailed mechanisms under those buckets have yet to be established. According to the article, that lack of clarity has already made it harder for universities to plan around the changes.
The same critique argues that researchers have been insufficiently engaged in shaping the reforms and warns that universities risk being treated as delivery agents rather than as valued collaborators. That matters because universities are not simply implementation bodies. They are where much of the UK’s discovery research, interdisciplinary capability, talent formation and early-stage innovation originate.
UKRI has acknowledged the anxiety. In his February update, Chapman said the organisation had been moving too quickly, committed to wider consultation on implementation, and stated that applicant-led research would remain protected overall. He also said the UKRI applicant-led budget would rise from £815 million in 2026 to 2027 to £866 million in 2029 to 2030, while a quarterly forward-looking planner would be introduced to improve visibility over future opportunities.
Those reassurances are important, but they do not remove the operational problem created by uncertainty. Chapman also confirmed that some funding routes had been temporarily paused, including changes affecting BBSRC, MRC and EPSRC, with the EPSRC Prosperity Partnership opportunity paused briefly so cross-UKRI input could widen its scope to other industrial strategy areas. For research-intensive institutions and sectors that rely on long planning cycles, even temporary disruption can have material effects.
This is why the wider financial position of universities matters so much. Universities UK estimates that government policy decisions will lead to an overall £3.7 billion reduction in funding to higher education providers in England between 2024 to 2025 and 2029 to 2030. Its analysis also points to growing cost and income pressures linked to immigration policy, pension and National Insurance changes, levies on international fees, and changes to teaching and research funding.
That context changes how UKRI’s reforms land in practice. A funding transition that might look manageable from the centre can be much more destabilising for institutions already dealing with tighter margins, rising costs and pressure on workforce planning. If that weakens the university research base, the downstream effects are likely to be felt across the commercial sectors that depend on it.
Advanced engineering needs to be explicit in this discussion, not treated as a background subset of manufacturing. In committee evidence, Chapman said that for each industrial strategy sector funded separately there will be a dedicated programme board, with a clearer front door across UKRI. Using quantum as an example, he said the front door would sit with the executive chair of EPSRC, supported by teams from across UKRI including STFC, Innovate UK and Research England.
That signals a more integrated route between university research, translational support, knowledge exchange and industrial application. Chapman also made clear that support for companies under bucket 3 is not limited to Innovate UK, but also includes Higher Education Innovation Funding and wider commercialisation and translation schemes. For advanced engineering businesses, that suggests the reforms could eventually produce a more coherent path from research capability to scale-up and adoption.
The same logic applies to life sciences and biotech. These sectors rely on long-horizon research, specialist facilities, translational capability and highly skilled people. If the reforms improve coordination without undermining the institutions that generate the science, they could strengthen the route from discovery to industrial value. If not, they risk weakening the upstream capability that later-stage innovation depends on.
That is particularly relevant for drug manufacturing and other research-intensive industries where commercial progress depends on the health of the wider ecosystem, not just on late-stage business support. Discovery science, collaboration, infrastructure and institutional stability all matter. A funding model that prioritises impact while destabilising the system that produces it would cut against its own stated objectives.
There is also a question of consistency. UKRI’s own stakeholder engagement guidance says effective engagement is not just about telling people about research, but about creating channels for reciprocal dialogue and mechanisms that allow that dialogue to effect meaningful change. The same guidance says early and continued engagement with business and industrial partners can help address commercialisation challenges and support successful translation.
NIHR guidance takes a similar line. It says applicants should show how relevant people and communities will shape different stages of the research lifecycle, how this work will be managed and resourced, and how its impact will be evaluated and shared. That makes the criticism of UKRI’s reform process more pointed. If funders expect partnership working and early engagement from applicants, there is a strong case that major funding reforms should reflect the same standard.
For businesses in life sciences, biotech, drug manufacturing, advanced manufacturing and advanced engineering, the practical question is not whether UKRI’s funding reforms sound strategically rational in the abstract. In broad terms, they do. The more important question is whether UKRI can combine clearer priorities with a stable university base, credible engagement and a predictable funding pipeline.
That point becomes even sharper when set against the UK’s wider talent ambitions. The government’s Global Talent Taskforce and £54 million Global Talent Fund are explicitly designed to attract world-class researchers and top-tier managerial and engineering talent into sectors tied to the industrial strategy, with UK universities positioned as part of that offer. If the UK wants to strengthen its position in high-value sectors, funding clarity and institutional stability will need to match that ambition.
The core test of UKRI’s funding reforms is not whether the new structure is easier to describe. It is whether the reforms create a stronger link between research excellence, industrial application and long-term economic value without damaging the university system that underpins all three. That is why universities and researchers need to be treated as strategic collaborators in the reform process, not as an afterthought.
For FI Group by EPSA’s audience, that is the real business issue. If the reforms are implemented with transparency, engagement and stability, they could help create a stronger pipeline from research to commercial growth. If they are not, the UK risks weakening the very research base that sectors such as life sciences and advanced engineering depend on. [1][2][4][5]
The UK government’s latest announcement on drugs manufactured in space matters because it starts to turn an emerging scientific concept into a more credible commercial pathway. On 5 March 2026, the UK Space Agency, MHRA, the Regulatory Innovation Office and the Civil Aviation Authority set out a coordinated package intended to help medicines developed in microgravity move from orbital research towards patient use on Earth. For UK pharmaceutical manufacturers and life sciences businesses, the significance is not simply scientific. It is regulatory, commercial and strategic. A clearer route to market makes it easier to assess whether space-enabled manufacturing is becoming a realistic part of future R&D and manufacturing portfolios. [1][2]
The government’s case rests on the unique conditions of microgravity. According to the official announcement, microgravity can improve how biologic drugs form, behave and work within the human body, with potential benefits for the quality, stability and performance of complex medicines. The same material links this to conditions such as cancer and rare diseases, which suggests the strongest near-term business case is likely to be in specialised, high-value therapies rather than commodity medicines. [1][2]
What has changed is not that the UK has created a separate medicines regime for space. It is that regulators are now spelling out more clearly how existing medicines regulation and spaceflight licensing can work together. The joint package includes regulatory guidance, principles-based case studies, a Re-entry Regulatory Sandbox and stronger supply-chain engagement, all designed to reduce uncertainty for businesses exploring in-orbit pharmaceutical activity. [1][2]
For life sciences companies, regulatory ambiguity has been one of the biggest obstacles to taking space manufacturing seriously. If a medicine is manufactured in orbit and then returned to Earth for patient use, businesses need confidence that the product can satisfy medicines regulation and that the mission itself can be licensed as a lawful spaceflight activity. The government’s latest intervention does not remove that complexity, but it does make the route more intelligible. [1][2]
The MHRA has indicated that existing medicines regulation can already support advanced and novel manufacturing approaches, including manufacturing that may take place in microgravity. In parallel, the UK’s spaceflight framework is described as flexible and outcome-focused, with the Civil Aviation Authority able to license novel in-orbit manufacturing missions under the current legislative structure. For businesses, that is significant because it suggests the UK is trying to adapt existing regulatory architecture to a new industrial environment rather than forcing companies to wait for an entirely new rulebook. [2]
This matters from a boardroom perspective because regulated sectors rarely invest seriously where legal and operational routes remain undefined. A clearer pathway does not make space manufacturing low risk, but it does reduce one of the major reasons for dismissing it as speculative. For UK businesses assessing long-term innovation bets, that is a meaningful shift. [1][2]
For pharmaceutical manufacturers, the practical question is not whether making drugs in space sounds futuristic. It is whether microgravity can deliver a measurable and defensible improvement in formulation, crystallisation, stability or delivery that could justify the cost and complexity involved. The strongest candidates are likely to be high-value medicines where even modest improvements in quality or manufacturability can create substantial clinical and commercial value. [1][2][4]
For biotech and life sciences firms, the announcement also changes the strategic conversation. It gives R&D leaders, regulatory teams and investors a better basis for asking which pipeline assets might genuinely benefit from microgravity, whether those benefits could be protected commercially, and how early regulatory engagement should be built into programme design. In effect, the UK is trying to shift space-enabled pharmaceuticals from the edge of the innovation agenda towards mainstream strategic evaluation. [1][2]
The announcement also sits within a broader UK growth narrative. The Life Sciences Sector Plan says the sector will be supported over the lifetime of the Spending Review by government funding of over £2 billion, alongside UKRI and NIHR funding. It also states that pharmaceutical R&D accounted for 17% of all UK business R&D in 2023, and sets the ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third most important globally by 2035. In that context, a clearer pathway for space-manufactured drugs is not an isolated policy curiosity. It fits into a broader attempt to strengthen the UK’s position in high-value R&D, commercialisation and manufacturing. [2][3]
The government’s package points to a wider value chain than pharmaceutical companies alone. Supply-chain engagement, case-study development, regulatory sandbox work and efforts to support licensing for in-orbit manufacturing platforms all indicate that the opportunity extends to specialist manufacturers, payload developers, space platform providers, logistics businesses, regulatory advisers and investors in enabling infrastructure. [1][2]
BioOrbit is currently the clearest example of how the UK wants this ecosystem to develop. The UK Space Agency has backed the company with a £250,000 feasibility study. Official material says the PHARM study is intended to design an end-to-end mission to manufacture drugs in microgravity, and that collaborative work with MHRA is helping clarify the regulatory pathway for in-orbit pharmaceutical manufacturing. That matters because it shows the policy is being tested against a live commercial use case rather than remaining purely theoretical. [1][2][4]
Companies should still read the announcement carefully. The UK has set out a clearer path, not a frictionless one. Businesses will still need to prove product quality, reproducibility, safety, manufacturing control, chain of custody, re-entry planning and commercial viability. The continuing emphasis on guidance, case studies and sandbox activity shows that this remains an emerging market rather than a settled operating model. [1][2]
For UK pharmaceutical manufacturers and life sciences businesses, the most useful next step is disciplined assessment. Which products in the pipeline might benefit materially from microgravity? Where could regulatory design become a bottleneck? What evidence would be needed to support reimbursement and market access if a medicine were partly manufactured in orbit? Businesses that can answer those questions early will be better placed than those treating space manufacturing as a branding exercise rather than a commercial and regulatory challenge. [1][2]
From a UK business perspective, the real significance of this announcement is that it lowers the cost of taking the opportunity seriously. It does not guarantee that drugs manufactured in space will become a mainstream category. It does, however, provide a more coherent framework for linking scientific research, mission licensing, regulatory planning and eventual patient access. For companies that want to lead in advanced biomanufacturing rather than follow later, that may prove to be the most important shift of all. [1][2][3]
Sources
[2] UK Government, Joint Statement from the UK Space Agency, the Medicines and Healthcare products Regulatory Agency, the Regulatory Innovation Office and the Civil Aviation Authority, GOV.UK, published 5 March 2026.
[3] UK Government, Life Sciences Sector Plan, GOV.UK, published 16 July 2025.
